AMGN · Amgen Inc
Price
Snapshot
50 fields · last close| Market Cap | $233.8B |
| P/E | 26.74 |
| Float | 538.4M |
| Beta | 0.44 |
| Volatility | 11.1% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mega cap |
| Macro sensitivity | Low |
| Clavix score | 78.3 |
| Price | 427.64 |
| Change | −1.12% |
| Prev Close | 432.49 |
| Open | 437.89 |
| Day Low | 431.39 |
| Day High | 438.82 |
| Avg Vol | 3 |
| Avg $ Vol | $1.15B |
| 52W High | 447.03 |
| 52W Low | 288.00 |
| 52W Pos | 87.8% |
| From High | −4.34% |
| From Low | +48.49% |
| Max DD 1Y | −16.57% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +3.45% |
| SMA 50 | +3.04% |
| SMA 200 | +15.90% |
| RSI (14) | 62.5 |
| Vol 30D | 41.6% |
| Vol 90D | 32.3% |
| 1Y Range | 288–447 |
| Daily bars | 899 |
| Perf Week | +4.25% |
| Perf Month | +13.88% |
| Perf Quarter | +18.76% |
| Perf Half Y | +23.51% |
| Perf Year | +46.21% |
| Perf YTD | +30.52% |
| Prev Day | −1.12% |
| Clavix | A- |
| Debt / Eq | 6.31 |
| Curr Ratio | 1.14 |
| Int Cover | 3.3× |
| FCF Margin | 22.0% |
| Rev Growth | +9.9% |
| Profit | Profitable |
| Leverage | Very High |
| Sector rank | 8 / 35 |
What AMGN does
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI.
The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD.
to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development.
The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Clavix risk grade
regraded every trading dayAMGN grades A-, 78.3 of 100. Steadiest on Macro Resilience (70), most exposed on Sector Resilience (55, mixed). 3 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 8 of 35 in Biotechnology by Clavix score.
How rough the ride is
| AMGN | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.44 | 0.51 |
| Volatilityannualized | 11.1% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −16.6% | — |
| Typical daily movemedian absolute daily change | 1.00% | — |
| Days beyond ±3%of the last 252 sessions | 21 (8%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| AMGN | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.44 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| AMGN | |
|---|---|
| 1 week | +4.2% |
| 1 month | +13.9% |
| Year to date | +30.5% |
| 1 year | +46.2% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| AMGN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 10 Sep |
| Average score0 most bearish, 100 most bullish | 59 |
| Bullish · bearisharticles above 60 · below 40 | 18 · 9 |
| Directionarticles whose tone is improving vs worsening | 18 ↑ 9 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| AMGN | |
|---|---|
| Revenue growthyear over year | +9.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openOn August 4, Amgen raised its revenue forecast for fiscal year 2026. Since the market close before that announcement, the stock is up 15.2%, well ahead of the S&P 500's 1.9% return over the same period.
The article compares Amgen and Merck, both yielding around 2.3%, and argues one is paying its dividend without sufficient cash to support it, while the other has room to grow. The body is too short to provide further detail.
Wall Street Zen downgraded Amgen from a buy rating to a hold rating in a Saturday research note. No further details, price target, or reasoning were provided.
Amgen raised its dividend by 6%, but the article warns that a large pile of acquisition debt, declining sales of older drugs, and a billion-dollar push into obesity medicines are all drawing from the same cash reserves.
Amgen raised its quarterly dividend 6% to $2.52 per share (about $10.08 annually), but the company carries $57.3 billion in total debt against $14 billion in cash, largely from the Horizon Therapeutics acquisition, while free cash flow of $8.1 billion in 2025 covered the $5.1 billion dividend payout. Management limited 2026 share buybacks to $3.0 billion, prioritizing dividend and debt reduction.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc | A- | $193.7B | 22.76 | 0.40 | Compare |
| VRTX | Vertex Pharmaceuticals Inc | B+ | $126.7B | 28.75 | 0.29 | Compare |
| ABBV | AbbVie Inc | B+ | $504.4B | 79.93 | 0.19 | Compare |
| MRNA | Moderna Inc | F | $87.04B | — | 1.17 | Compare |
| REGN | Regeneron Pharmaceuticals Inc | B+ | $81.41B | 18.81 | 0.13 | Compare |
| NTRA | Natera Inc | B- | $56.71B | — | 1.54 | Compare |
| RVMD | Revolution Medicines Inc | B- | $38.14B | — | 1.44 | Compare |
| BIIB | Biogen Inc | B+ | $34.37B | 41.19 | 0.10 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.